High-dose risedronate treatment partially preserves cancellous bone mass and microarchitecture during long-term disuse

Bone

Volumn 37, Issue 3, 2005, Pages 287-295

  Li, Chao Yang ^a   Majeska, Robert J ^a   Laudier, Damien M ^a   Mann, Richard ^b   Schaffler, Mitchell B ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Bisphosphonate; Bone histomorphometry; Bone remodeling; Disuse osteoporosis; Risedronate

Indexed keywords

CALCEIN; RISEDRONIC ACID; WATER;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE MASS; CANCELLOUS BONE; CONTROLLED STUDY; DOG; DRUG MEGADOSE; DRUG POTENCY; FEMALE; FORELIMB; IMMOBILIZATION; LONG TERM CARE; METACARPAL BONE; MORPHOMETRICS; NONHUMAN; OSSIFICATION; OSTEOCLAST; OSTEOID; OSTEOLYSIS; SURFACE PROPERTY; TRABECULAR BONE;

ANIMALS; BONE AND BONES; BONE DENSITY; DOGS; ETIDRONIC ACID; FEMALE; IMMOBILIZATION;

EID: 23844459332     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2005.04.041     Document Type: Article

References (55)

1. P.W. Nance, O. Schryvers, W. Leslie, S. Ludwig, J. Krahn, and D. Uebelhart Intravenous pamidronate attenuates bone density loss after acute spinal cord injury Arch. Phys. Med. Rehabil. 80 1999 243 251
2. E.G. Pearson, P.W. Nance, W.D. Leslie, and S. Ludwig Cyclical etidronate: its effect on bone density in patients with acute spinal cord injury Arch. Phys. Med. Rahabil. 78 1997 269 272
3. K.E. Poole, E.A. Warburton, and J. Reeve Rapid long-term bone loss following stroke in a man with osteoporosis and atherosclerosis Osteoporos. Int. 6 2005 302 305
4. P. Minaire, E. Berard, P.J. Meunier, C. Edouard, G. Goedert, and G. Pilonchery Effects of disodium dichloromethylene diphosphonate on bone loss in paraplegic patients J. Clin. Invest. 68 1981 1086 1092
5. Y. Sato, T. Asoh, M. Kaji, and K. Oizumi Beneficial effect of intermittent cyclical etidronate therapy in hemiplegic patients following an acute stroke J. Bone Miner. Res. 15 2000 2487 2494
6. D. Chappard, P. Minaire, C. Privat, E. Berard, J. Mendoza-Sarmiento, and H. Tournebise Effects of tiludronate on bone loss in paraplegic patients J. Bone Miner. Res. 10 1995 112 118
7. J. Kanis, A. Oden, and O. Johnell Acute and long-term increase in fracture risk after hospitalization for stroke Stroke 32 2001 702 706
8. T. Lang, A. LeBlanc, H. Evans, Y. Lu, H. Genant, and A. Yu Cortical and trabecular bone mineral loss from the spine and hip in long-duration spaceflight J. Bone Miner. Res. 19 2004 1006 1012
9. S. Epstein, A.M. Inzerillo, J. Caminis, and M. Zaidi Disorders associated with acute rapid and severe bone loss J. Bone Miner. Res. 18 2003 2083 2094
10. H. Genant, C. Cooper, G. Poor, L. Reid, G. Ehrlich, and J. Kanis Interim report and recommendations of the World Health Organization task-force for osteoporosis Osteoporos. Int. 10 1999 259 264
11. N.B. Watts Risedronate for the prevention and treatment of postmenopausal osteoporosis: results from recent clinical trials Ostoporos. Int. Suppl 3 2001 S17 S22
12. J.Y. Reginster, H.W. Minne, O.H. Sorensen, M. Hooper, C. Roux, and M.L. Brandi Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis Ostoporos. Int. 11 2000 83 91
13. E.F. Eriksen, F. Melsen, E. Sod, I. Barton, and A. Chines Effects of long-term risedronate on bone quality and bone turnover in women with postmenopausal osteoporosis Bone 31 2002 620 625
14. J.P. Brown, A.A. Chines, W.R. Myers, R.A. Eusebio, C. Ritter-Hrncirik, and C.W. Hayes Improvement of pagetic bone lesions with risedronate treatment: a radiologic study Bone 26 2000 263 267
15. J.D. Adachi, W.G. Bensen, J. Brown, D. Hanley, A. Hodsman, and R. Josse Intermittent cyclical etidronate therapy to prevent corticosteroid-induced osteoporosis N. Engl. J. Med. 337 1997 382 387
16. E.M.C. Lau, J. Woo, Y.H. Chan, and M. Li Alendronate for the prevention of bone loss in patients on inhaled steroid therapy Bone 29 2001 506 510
17. S. Wallach, S. Cohen, D.M. Reid, R.A. Hughes, D.J. Hosking, and R.F. Laan Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy Calcif. Tissue Int. 67 2000 277 285
18. D.M. Reid, S. Adami, J.P. Devogelaer, and A.A. Chines Risedronate increases bone density and reduces vertebral fracture risk within one year in men on corticosteroid therapy Calcif. Tissue Int. 69 2001 242 247
19. C.Y. Li, D. Laudier, and M.B. Schaffler Remobilization restores cancellous bone mass but not microarchiteture after long-term disuse in older adult dogs Trans. ORS 28 2003 1052
20. C.Y. Li, C. Price, K. Delisser, P. Nasser, D. Laudier, and M. Clement Long-term disuse osteoporosis appears less sensitive to bisphosphonate treatment than other osteoporosis J. Bone Miner. Res. 20 2005 117 124
21. T. Mashiba, C.H. Turner, T. Hirano, M.R. Forwood, C.C. Johnston, and D.B. Burr Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles Bone 28 2001 524 531
22. Z.F.G. Jaworski, and H.K. Uhthoff Reversibility of nontraumatic disuse osteoporosis during its active phase Bone 7 1986 431 439
23. H.K. Uhthoff, G. Sékaly, and Z.F.G. Jaworski Effect of long-term nontraumatic immobilization on metaphyseal spongiosa in young adult and old beagle dogs Clin. Orthop. 182 1985 278 283
24. A.M. Parfitt, F.H. Glorieux, J.A. Kanis, H. Malluche, P.J. Meunier, and S.M. Ott Bone histomorphometry nomenclature, symbols and units: report of the ASBMR histomorphometry nomenclature committee J. Bone Miner. Res. 2 1987 595 610
25. R.G. Erben, L. Mosekilde, J.S. Thomsen, K. Weber, K. Stahr, and A. Leyshon Prevention of bone loss in ovariectomized rats by combined treatment with risedronate and 1,25-dhydronxyvitamin D3 J. Bone Miner. Res. 17 2002 1498 1511
26. S.Y. Smith, R.R. Recker, M. Hannan, R. Müller, and F. Bauss Intermittent intravenous administration of the bisphosphonate ibandronate prevents bone loss and maintains bone strength and quality in ovariectomized cynomolgus monkeys Bone 32 2003 45 55
27. R. Balena, B.C. Toolan, M. Shea, A. Markatos, E.R. Myers, and S.C. Lee The effects of 2-year treatment with the aminobisphosphonate alendronate on bone metabolism, bone histomorphometry, and bone strength in ovariectomized nonhuman primates J. Clin. Invest. 92 1993 2577 2586
28. J. Li, S. Mori, T. Mashiba, Y. Kaji, M. Taki, and S. Komatsubara Preadministration of incadronate disodium can prevent bone loss in rat proximal tibial metaphysis when induced by hindlimb immobilization by bandage Bone 23 1998 459 463
29. S. Bourrin, P. Ammann, J.P. Bonjour, and R. Rizzoli Recovery of proximal tibia bone mineral density and strength, but not cancellous bone architecture, after long-term bisphosphonate or selective estrogen receptor modulator therapy in aged rats Bone 30 2002 195 200
30. M.J. Rogers, S. Gordon, H.L. Benford, F.P. Coxon, S.P. Luckman, and J. Monkkonen Cellular and molecular mechanisms of action of bisphosphonates Cancer 88 2000 2961 2978
31. J.R. Green Bisphosphonates: preclinical review The Oncologist 9 Suppl 4 2004 3 13
32. P. Minaire, J. Depassio, E. Berard, P.J. Meunier, C. Edouard, and G. Pilonchery Effects of clodronate on immobilization bone loss Bone 8 Suppl 1 1987 S63 S68
33. N. Bravenboer, S.E. Papapoulos, P. Holzmann, N.AT. Hamdy, J.C. Netelenbos, and P. Lips Bone histomorphometric evaluation of pamidronate treatment in clinically manifest osteoporosis Osteoporos. Int. 9 1999 489 493
34. P.M. Chavassieux, M.E. Arlot, C. Reda, L. Wei, A.J. Yates, and P.J. Meunier Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis J. Clin. Invest. 100 1997 1475 1480
35. J.M. Halasy-Nagy, G.A. Rodan, and A.A. Reszka Inhibition of bone resorption by alendronate and risedronate does not require osteoclast apoptosis Bone 29 2001 553 559
36. R.R. Recker, R.S. Weinstein, C.H. Chesnut III, R.C. Schimmer, P. Mahoney, and C. Hughes Histomorphometric evaluation of daily and intermittent oral ibandronate in women with postmenopausal osteoporosis: results from the BONE study Osteoporos. Int. 15 2004 231 237
37. S. Komatsubara, S. Mori, T. Mashiba, M. Ito, J. Li, and Y. Kaji Long-term treatment of incadronate disodium accumulates microdamage but improves the trabecular bone microarchitecture in dog vertebra J. Bone Miner. Res. 18 2003 512 520
38. T. Mashiba, C.H. Turner, T. Hirano, M.R. Forwood, D.S. Jacob, and C.C. Johnston Effects of high-dose etidronate treatment on microdamage accumulation and biomechanical properties in beagle bone before occurrence of spontaneous fractures Bone 29 2001 271 278
39. M.R. Forwood, D.B. Burr, Y. Takano, D.F. Eastman, P.N. Smith, and J.D. Schwardt Risedronate treatment does not increase microdamage in the canine femoral neck Bone 16 1995 643 650
40. R. Kiviranta, J. Morko, S.L. Alatalo, R. NicAmhlaoibh, J. Risteli, and T. Laitala-Leinonen Impaired bone resorption in cathepsin K-deficient mice is partially compensated for by enhanced osteoclastogenesis and increased expression of other proteases via an increased RANKL/OPG ratio Bone 36 2005 159 172
41. C.Y. Li, B.D. Gelb, D.M. Laudier, Y. Ni, J. Zhang, and G. Opdenakker Mmp 9 plays a critical role in bone remodeling in the absence of cathepsin K Trans. Orthop. Res. Soc. 30 2005 879
42. N.E. Lane, A.J. Kaneps, S.M. Stover, G. Modin, and D.B. Kimmel Bone mineral density and turnover following forelimb immobilization and recovery in young adult dogs Calcif. Tissue Int. 59 1996 401 406
43. M.D. Grynpas, M. Kasra, R. Renlund, and K.P.H. Pritzker The effect of pamidronate in a new model of immobilization in the dog Bone 17 4 Suppl. 1995 S225 S232
44. A. Caillot-Augusseau, M.H. Lafage-Proust, C. Soler, J. Pernod, F. Dubois, and C. Alexandre Bone formation and resorption biological markers in cosmonauts during and after a 180-day space flight (Euromir 95) Clin. Chem. 44 1998 578 585
45. J.E. Zerwekh, L.A. Ruml, F. Gottschalk, and C.Y.C. Pak The effects of twelve weeks of bed rest on bone histology, biochemical markers of bone turnover, and calcium homeostasis in eleven normal subjects J. Bone Miner. Res. 13 1998 1594 1601
46. A. Chantraine, B. Nusgens, and C.M. Lapierre Bone remodeling during the development of osteoporosis in paraplegia Calcif. Tissue Int. 38 1986 323 327
47. G.L. Mechanic, D.R. Young, A.J. Banes, and M. Yamauchi Nonmineralized and mineralized bone collagen in bone of immobilized monkeys Calcif. Tissue Int. 39 1986 63 68
48. D. Roberts, W. Lee, R.C. Cuneo, J. Wittmann, G. Ward, and R. Flatman Longitudinal study of bone turnover after acute spinal cord injury J. Clin. Endocrinol. Metab. 83 1998 415 422
49. M.B. Schaffler, and H.Q. Pan Bone cell kinetics in the adult canine skeleton during immobilization Trans. Orthop. Res. Soc. 18 1993 633
50. H. Takahashi, H. Norimatsu, G. Watanabe, T. Konno, J. Inoue, and M. Fukada The remodeling period (sigma) in canine and human cortical bone Y. Yoshitoshi T. Fujita Calcium Endocrinology 1980 Chugai Igaku Tokyo 13 31
51. X.J. Li, W.S. Jee, Y.L. Li, and P. Patterson-Buckendahl Transient effects of subcutaneously administered prostaglandin E2 on cancellous and cortical bone in young adult dogs Bone 11 1990 353 364
52. C. Anderson, and K.D. Danylchuk Age-related variations in cortical bone-remodeling measurements in male beagles 10 to 26 months of age Am. J. Vet. Res. 40 1979 869 872
53. J.R. Shapiro, and V. Schneider Countermeasure development: future research targets J. Gravit. Physiol. 7 2000 1 4
54. V.S. Schneider, A. LeBlanc, and C.L. Huntoon Prevention of space flight induced soft tissue calcification and disuse osteoporosis Acta Astronaut. 29 1993 139 140
55. C. Christiansen, R. Phipps, D. Burgio, L. Sun, D. Russell, and B. Keck Comparison of risedronate and alendronate pharmacokinetics at clinical doses Osteoporos. Int. 14 Suppl. 7 2003 S38